Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Bos taurus | Nitric-oxide synthase, endothelial | No references | |
Rattus norvegicus | Nitric-oxide synthase, brain | No references | |
Mus musculus | nitric oxide synthase 2, inducible | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0091 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0091 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0045 | 0 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0091 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0091 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0081 | 0.7743 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0045 | 0 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0046 | 0.0151 | 0.0151 |
Brugia malayi | FAD binding domain containing protein | 0.0091 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0056 | 0.2407 | 0.2407 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0091 | 1 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0091 | 1 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0056 | 0.2407 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0091 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0091 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0081 | 0.7743 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0091 | 1 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0091 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0091 | 1 | 0.5 |
Leishmania major | p450 reductase, putative | 0.0091 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0091 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0091 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0091 | 1 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0091 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0091 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | = 212 nM | Inhibition Assay | BINDINGDB. | No reference |
Ki (binding) | = 9890 nM | Inhibition Assay | BINDINGDB. | No reference |
Ki (binding) | = 19200 nM | Inhibition Assay | BINDINGDB. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.